S5068

Salmeterol xinafoate

≥98% (HPLC), solid

• Sinónimos: (±) 4-Hydroxy-a1-[[[6-(4-phenylbutoxy)hexyl]amino]m-ethyl]-1,3-benzenedimethanol xinafoate, GR 33343X xinafoate
• Fórmula empírica (notación de Hill): C₂₅H₃₇NO₄ · C₁₁H₈O₃
• Número de CAS: 94749-08-3
• Peso molecular: 603.75
• MDL number: MFCD00897708
• UNSPSC Code: 12352200
• PubChem Substance ID: 24278713
• NACRES: NA.77

Propiedades

• assay: ≥98% (HPLC)
• form: solid
• color: white
• solubility: H₂O: slightly soluble; ethanol: slightly soluble; methanol: freely soluble
• originator: GlaxoSmithKline
• SMILES string: OC(=O)c1ccc2ccccc2c1O.OCc3cc(ccc3O)C(O)CNCCCCCCOCCCCc4ccccc4
• InChI: 1S/C25H37NO4.C11H8O3/c27-20-23-18-22(13-14-24(23)28)25(29)19-26-15-7-1-2-8-16-30-17-9-6-12-21-10-4-3-5-11-21;12-10-8-4-2-1-3-7(8)5-6-9(10)11(13)14/h3-5,10-11,13-14,18,25-29H,1-2,6-9,12,15-17,19-20H2;1-6,12H,(H,13,14)
• InChI key: XTZNCVSCVHTPAI-UHFFFAOYSA-N
• Gene Information: human ... ADRB2(154)

Descripción

Application

Salmeterol xinafoate was used as conjugate with human serum albumin to study the immune responses in rabbits.⁷

Biochem/physiol Actions

Salmeterol xinafoate is a β2 adrenoceptor agonist with longer lasting bronchodilation and anti-inflammatory effects. It relaxes the airway smooth muscles, stabilizes mast cells and regulates the release of histamine. Salmetrol is particularly effective in treatment of mild asthma, chronic obstructive pulmonary disorder.^5,6

β₂-adrenoceptor agonist.

Features and Benefits

This compound was developed by GlaxoSmithKline. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Información de seguridad

• Storage Class: 11 - Combustible Solids
• wgk_germany: WGK 3
• flash_point_f: Not applicable
• flash_point_c: Not applicable
• ppe: Eyeshields, Gloves, type N95 (US)